BiochemProbe — Life Science Research Reagents

TC-FPR 43 free base

FPR Agonist 43 is a dual formyl peptide receptor 1 and formyl peptide receptor 2/ALX agonist.

For research use only. Not for human or veterinary use.

Purity >98% Stock Inquire

TC-FPR 43 structure

CAS No.: 903895-98-7

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
250 mg USD 600.00 BP-02245-250mg In stock Get quote
500 mg USD 950.00 BP-02245-500mg In stock Get quote
1 g USD 1,450.00 BP-02245-1g In stock Get quote
5 g Inquire BP-02245-5g In stock Inquire
10 g Inquire BP-02245-10g In stock Inquire

Need another size or custom synthesis? Request a quote.

Description

FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist.

Biological activity

In Vitro FPR Agonist 43 (10-5-107 nM) is actively potent in the cAMP assay in FPR2/ALX over-expressing CHO cells. FPR Agonist 43 is also active in the GTPγ binding assay (IC50=207±51 nM). FPR1 is the preferred receptor for FPR Agonist 43 in in both human neutrophils and possibly also in mouse cells.

Identifiers

SMILES
O=C(NC1=C(C(C)C)N(C)N(C2=CC=CC=C2)C1=O)NC3=CC=C(Cl)C=C3
InChIKey
PAEBEUZTAPIOIO-UHFFFAOYSA-N

Specifications

MW (average)
384.8590
Formula
C20H21ClN4O2
CAS No.
903895-98-7
Physical state
Solid
Color
white to light yellow
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder 4℃, sealed storage, away from moisture; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO : 37.5 mg/mL H2O : < 0.1 mg/mL

In vitro
Soluble in DMSO : 37.5 mg/mL H2O : < 0.1 mg/mL

References

[1]. Planagumà A, et al. Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clin Exp Immunol. 2013 Aug;173(2):298-309.
[2]. Forsman H, et al. What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4? Scand J Immunol. 2011 Sep;74(3):227-234.

Same research area

Search Inflammation/Immunology

Recently viewed